Just a few neoantigens may be enough for T cells to control
By A Mystery Man Writer
Description
In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.
Schematic illustration of neoantigen-based cancer immunotherapy
Engineering T cells - by Eric Topol - Ground Truths
Personalized cancer vaccine and adoptive T cell therapy benefits patients with advanced ovarian cancer: Study
Silencing TAP makes the tumor a little louder
Tumor Antigen Targets for Personalized Adoptive T Cell Therapies
When neoantigen expression is low, the T cells won't go
B cells and CD4+ T cells are the stage crew for antitumor immunity
Frontiers Neoantigen: A New Breakthrough in Tumor Immunotherapy
Induction of neoantigen-reactive T cells from healthy donors
Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma
Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function - ScienceDirect
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges, Biomarker Research
Overcoming tumor antigen heterogeneity in CAR-T cell therapy for malignant mesothelioma (MM)
Inducing optimal antitumor T cells by combining vaccination and checkpoint therapy
from
per adult (price varies by group size)